OrbiMed Asia GP IV, L.P. insider trades: ArriVent Biopharma (AVBP) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where OrbiMed Asia GP IV, L.P. reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 30, 2024 | AVBP | ↑ Buy | 222,222 | $18.00 | $4.0M | Indirect | Jan 31, 2024 (1d) |
| May 5, 2023 | KNTE | ↑ Buy | 1,377,473 | $2.80 | $3.9M | Indirect | May 8, 2023 (3d) |
| May 2, 2023 | KNTE | ↑ Buy | 1,346,342 | $2.61 | $3.5M | Indirect | May 2, 2023 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other AVBP insiders
Open-market trades in the last 12 months
About OrbiMed Asia GP IV, L.P.'s insider trades
OrbiMed Asia GP IV, L.P. is a director at ArriVent Biopharma (AVBP). Since May 2, 2023, it has reported 3 open-market purchases worth $11.4M and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Its filings also include shares returned to the company (1 filing), conversions (1 filing), grants and awards (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AVBP insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.